The authors reply:
To the Editor: Parikh and Ellison correctly note that from the patient's perspective, improvement in the short-term and long-term survival of renal transplants is additive and directly affects the prognosis.
We found that there has been steady improvement in the survival of renal transplants since the introduction of cyclosporine in the 1980s. Over 90 percent of the 1988 cohort received cyclosporine, and therefore the improved outcomes in later cohorts could be related to changes in doses or timing. 1 However, the improvement is probably not related to cyclosporine alone. The causes of this improvement cannot be pinpointed, but they include a reduction in episodes of acute rejection and improvements in the control of hypertension and in the prevention and management of infections. The decrease in panel-reactive antibodies is probably due to a reduction in the transfusion rate (15 percent with more than 10 prior transfusions in 1988 vs. less than 4 percent after 1992), a decrease that is correlated with the introduction of erythropoietin.
Sam and Leehey raise a question about discrepancies between the text and Table 2 of our article with respect to the improvement in the projected half-life of transplants in blacks, nonblacks, and all recipients. The projected half-life values given in the text (7.2 years for blacks and 13.3 years for nonblacks) were for 1994, not 1995; the value of 11.0 years for all recipients of cadaveric transplants, shown in Table 2 
Prevalence of Gynecologic Cancer in Women Exposed to Diethylstilbestrol in Utero
To the Editor: Exposure to diethylstilbestrol (DES) in utero is related to an increased risk of clear-cell adenocarcinoma of the vagina and cervix at a young age. 1 However, the long-term risk of cancer in the daughters of women given DES during pregnancy (DES daughters) is still unknown. To date, only one study has examined the risk of cancer in adult DES daughters, and no increased risks were found in that study, except for an increased risk of clearcell adenocarcinoma of the vagina and cervix. 2 We analyzed data from a questionnaire mailed to 13,350 DES daughters registered at the Netherlands DES Information Center. Self-reported information on cancer was validated by reviewing information from medical records. Prevalence ratios for cases of cancer were calculated as the ratio of the observed number of cases to the expected number, on the basis of age-specific and calendar-periodspecific prevalence rates based on data from the Eindhoven Cancer Registry. The 95 percent confidence intervals and the statistical power (with an alpha level of 0.05) were calculated on the basis of a Poisson distribution. 3 To quantify selection bias, we also calculated the prevalence of melanoma and colon cancer, for which no association with DES was assumed, as "marker" tumors. Cases of clear-cell adenocarcinoma of the vagina and cervix were excluded from the analysis.
Forty-one percent of the women (5421) responded to the mailing. The median age of the respondents was 30 years (range, 19 to 45). A total of 111 cancers were reported by 105 women, and the medical records of 85 of these women were reviewed to confirm the reported tumors ( Table 1) . The agreement between the information reported by the respondents and the information from the medical records was poor for cervical cancer (21 percent), since many women reported a carcinoma in situ as an invasive cancer. The prevalence ratio for confirmed cervical cancer was significantly elevated (5.4; 95 percent confidence interval, 2.8 to 9.5); the prevalence ratios for the other tumors were not significantly elevated.
*The expected number of tumors was calculated on the basis of age-and period-specific prevalence rates according to data from the Eindhoven Cancer Registry. †CI denotes confidence interval. ‡The values indicate the probability that the null hypothesis is rejected at an alpha level of 0.05 in favor of the alternative hypothesis. §There were 10 squamous-cell carcinomas and 2 adenocarcinomas. ¶The tumors included two borderline carcinomas.
¿A total of 111 tumors were reported by 105 DES daughters. **The medical records of 85 DES daughters who reported a total of 89 tumors were reviewed. † †A total of 33 tumors reported by 33 DES daughters were confirmed by a review of the medical records. DES daughters with health problems might have been more likely to respond to our questionnaire than DES daughters without health problems. However, adjustment for the elevated prevalence ratio for the combined marker tumors (1.6; 95 percent confidence interval, 0.6 to 3.3) still resulted in a tripled risk of cervical cancer. DES daughters might actually be expected to have a lower prevalence of invasive cervical cancer than women in the general population, since DES daughters are screened more intensively for cervical cancer and since precursor lesions detected on screening are usually treated aggressively. Our finding is therefore particularly striking.
Robboy and colleagues reported that the risk of squamous-cell dysplasia and carcinoma in situ was doubled in DES daughters. 4 They hypothesized that DES daughters might have an elevated risk of cervical cancer because of the presence of a wider transformation zone of metaplastic squamous epithelium, which might make them more susceptible to external carcinogenic factors. Larger studies, preferably with incidence data, are needed to confirm our observations. J ANNEKE V ERLOOP , M.S C . M ATTI A. ROOKUS, PH.D. FLORA E. VAN 
